PT - JOURNAL ARTICLE AU - Masahiro Kanai AU - Roy Elzur AU - Wei Zhou AU - Global Biobank Meta-analysis Initiative AU - Mark J Daly AU - Hilary K Finucane TI - Meta-analysis fine-mapping is often miscalibrated at single-variant resolution AID - 10.1101/2022.03.16.22272457 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.16.22272457 4099 - http://medrxiv.org/content/early/2022/03/20/2022.03.16.22272457.short 4100 - http://medrxiv.org/content/early/2022/03/20/2022.03.16.22272457.full AB - Meta-analysis is pervasively used to combine multiple genome-wide association studies (GWAS) into a more powerful whole. To resolve causal variants, meta-analysis studies typically apply summary statistics-based fine-mapping methods as they are applied to single-cohort studies. However, it is unclear whether heterogeneous characteristics of each cohort (e.g., ancestry, sample size, phenotyping, genotyping, or imputation) affect fine-mapping calibration and recall. Here, we first demonstrate that meta-analysis fine-mapping is substantially miscalibrated in simulations when different genotyping arrays or imputation panels are included. To mitigate these issues, we propose a summary statistics-based QC method, SLALOM, that identifies suspicious loci for meta-analysis fine-mapping by detecting outliers in association statistics based on ancestry-matched local LD structure. Having validated SLALOM performance in simulations and the GWAS Catalog, we applied it to 14 disease endpoints from the Global Biobank Meta-analysis Initiative and found that 68% of loci showed suspicious patterns that call into question fine-mapping accuracy. These predicted suspicious loci were significantly depleted for having likely causal variants, such as nonsynonymous variants, as a lead variant (2.8x; Fisher’s exact P = 6.2 × 10−4). Compared to fine-mapping results in individual biobanks, we found limited evidence of fine-mapping improvement in the GBMI meta-analyses. Although a full solution requires complete synchronization across cohorts, our approach identifies likely spurious results in meta-analysis fine-mapping. We urge extreme caution when interpreting fine-mapping results from meta-analysis.Competing Interest StatementM.J.D. is a founder of Maze Therapeutics. All other authors declare no competing interests.Funding StatementM.K. was supported by a Nakajima Foundation Fellowship and the Masason Foundation. H.K.F. was funded by NIH grant DP5 OD024582. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves only openly available GWAS summary statistics, which can be obtained from: * the Global Biobank Meta-analysis Initiative, https://www.globalbiobankmeta.org/resources * the GWAS Catalog, https://www.ebi.ac.uk/gwas/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe GBMI summary statistics for the 14 endpoints are available at https://www.globalbiobankmeta.org/resources and are browserble at the GBMI PheWeb website (http://results.globalbiobankmeta.org/). https://www.globalbiobankmeta.org/resources http://results.globalbiobankmeta.org/